cyproheptadine has been researched along with Carcinoma, Ovarian Epithelial in 1 studies
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.
Carcinoma, Ovarian Epithelial: A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we aimed to evaluate the prognostic value of PAFR in epithelial ovarian cancer (EOC) and the potential use of its antagonist, rupatadine, as an experimental treatment." | 4.02 | The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine. ( Beyer, S; Burges, A; Chelariu-Raicu, A; Czogalla, B; Deuster, E; Hester, A; Hysenaj, I; Jeschke, U; Kahaly, M; Kolben, T; Kraus, F; Mahner, S; Mayr, D; Schmoeckel, E; Trillsch, F, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deuster, E | 1 |
| Hysenaj, I | 1 |
| Kahaly, M | 1 |
| Schmoeckel, E | 1 |
| Mayr, D | 1 |
| Beyer, S | 1 |
| Kolben, T | 1 |
| Hester, A | 1 |
| Kraus, F | 1 |
| Chelariu-Raicu, A | 1 |
| Burges, A | 1 |
| Mahner, S | 1 |
| Jeschke, U | 1 |
| Trillsch, F | 1 |
| Czogalla, B | 1 |
1 other study available for cyproheptadine and Carcinoma, Ovarian Epithelial
| Article | Year |
|---|---|
The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine.
Topics: Aged; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cyproheptadine; ErbB Rece | 2021 |